Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Barcelona | OTHER |
| Associació Vallès Amics de la Neurologia | OTHER |
| Fundació La Marató de TV3 | OTHER |
Background: Mild Cognitive Impairment (MCI) is a risk factor for dementia and represents a critical window of opportunity to intervene and alter the trajectory of both cognitive and functional decline. Emerging life-logging technologies has shown a tremendous potential to increase autobiographical memory.
Objective: The main goal of the present study is to develop a Cognitive Training program (CT) for MCI based on life-logging captured by a Wearable Camera (WeC) recording specific autobiographical episodes for stimulating posteriorly episodic memory. The challenge is to create an application to manage this large collection of images, which can be easily retrieved as events by users in a therapeutic context as a multimodal cognitive stimulation. The investigators will conduct a quasi-experimental design with non-equivalent control group, evaluating the effectiveness of the life-logging re-experiencing program immediately and 3-month follow-up period.
Methodology: The design is a pretest, posttest and follow-up design, where 30 adults with MCI were sequentially allocated to one of two conditions: intervention or control group. All subjects wore a lifelogging WeC during two weeks, and subsequently they were generated several videos with the most relevant information of each event. Subjects in the Intervention Group will attend 1-hour individual training sessions 2 times per week for 14 8 weeks. Main outcomes measures will be cognitive, functional, emotional and quality of life measures, as well as biochemical measures (BDNF).
Expected results: The investigators expect the outcomes to provide preliminary evidence that autobiographical experimentation CT programs can positively impact cognitive functioning and may represent an effective strategy to improve memory and functionality in those who begun to experience cognitive decline.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental intervention | Experimental | ReMemory-MCI training |
|
| Control intervention | Active Comparator | Control intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ReMemory-MCI training | Behavioral |
| ||
| Control intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Change in memory after receiving treatment | Memory was measured using the Logical Memory Test from the Wechsler Memory Scale, IV version (WMS-IV, Spanish version); the International Shopping List Task and the One Card Learning Task from the computerized neurocognitive battery Cogstate. | after 16 sessions treatment and 3 months |
| Change in attention after receiving treatment | Attention was measured using the Identification Task from the computerized neurocognitive battery Cogstate and the Forward Digit Span from the Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV) | after 16 sessions treatment and 3 months |
| Change in working memory after receiving treatment | orking memory was measured using the One Back Task from the computerized neurocognitive battery Cogstate and the Backward Digit Span from the Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV). | after 16 sessions treatment and 3 months |
| Change in executive function, set-shifting after receiving treatment | Set-shifting was measured using the Colors Trails Test | after 16 sessions treatment and 3 months |
| Change in executive function,verbal fluency | erbal Fluency was measured using the Controlled Oral Word Association Test, spanish adaptation, and semantic fluency test using the category Animals | after 16 sessions treatment and 3 months |
| Change in executive function, inhibition after receiving treatment | Inhibition was measured using the Five Digit Test |
| Measure | Description | Time Frame |
|---|---|---|
| Change in subjective memory complaints after receiving treatment | subjective memory complaints was measured using Memory Faiures of EveryDay (MFE) Test | after 16 sessions treatment and 3 months |
| Change in functional capacity after receiving treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maite Garolera, PhD | Consorci Sanitari de Terrassa | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Behavioral |
|
| after 16 sessions treatment and 3 months |
| Change in processing speed after receiving treatment | Processing speed was measured using the Detection Task from the computerized neurocognitive battery Cogstate battery | after 16 sessions treatment and 3 months |
Functional capacity was measured using Functional Assessment Questionnaire (FAQ) and the UCSD Performance-Based Skills Assessment (UPSA).
| after 16 sessions treatment and 3 months |
| Change in depression and anxiety after receiving treatment | depression and anxiety were measured using the Hospital Anxiety and Depression Scale (HADS) | after 16 sessions treatment and 3 months |
| Change in quality of life | Quality of life was measured using Quality of Life-Alzheimer Disease (QoL-AD) | after 16 sessions treatment and 3 months |
| Change in Neuropsychiatric symptoms | Neuropsychiatric symptoms was measured using Neuropsychiatric Inventory Questionnaire (NPI) | after 16 sessions treatment and 3 months |
| Change in Caregiver Burden | Caregiver Burden was measured using the Zarit Caregiver Burden Scale | after 16 sessions treatment and 3 months |
| Change in patient's self-esteem | Self-Esteem was measured using the Rosenberg Self-Esteem Scale | after 16 sessions treatment and 3 months |
| Change in patient and caregiver's perception of social support | Perception of social support was measured using the Duke-UNC Functional Social Support Questionnaire | after 16 sessions treatment and 3 months |
| Change in neuroplasticiy | neuroplasticiy was measured using Brain-derived neutrophic factor (BDNF) serum levels | after 16 sessions treatment and 3 months |